A once-daily cancer pill that cut the risk of death by 60 per cent in patients with advanced pancreatic cancer has been approved in the US, nearly doubling median survival compared with standard chemotherapy.
The FDA cleared Rasonque, also known as Daraxonrasib, on Wednesday for adults with previously treated metastatic pancreatic ductal adenocarcinoma, offering a new option for people facing one of the world's deadliest cancers.
